Found: 14
Select item for more details and to access through your institution.
Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Short-Term Effects of the Long-Acting Insulin Analog Detemir and Human Insulin on Plasma Levels of Insulin-Like Growth Factor-I and Its Binding Proteins in Humans.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2009, v. 94, n. 8, p. 3017, doi. 10.1210/jc.2008-2838
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2007, v. 30, n. 5, p. 1261, doi. 10.2337/dc06-2208
- By:
- Publication type:
- Article
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL<sup>-1</sup> and Insulin Degludec 100 units · mL<sup>-1</sup> in Type 1 Diabetes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin.
- Published in:
- Diabetes Care, 2015, v. 38, n. 7, p. e96, doi. 10.2337/dc14-2662
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 503, doi. 10.2337/dc14-0649
- By:
- Publication type:
- Article
Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2012, v. 35, n. 12, p. 2647, doi. 10.2337/dc12-0271
- By:
- Publication type:
- Article
Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Care, 2011, v. 34, n. 12, p. 2521, doi. 10.2337/dc11-1064
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects.
- Published in:
- Diabetes Care, 2011, v. 34, n. 6, p. 1312, doi. 10.2337/dc10-1911
- By:
- Publication type:
- Article
895-P: Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-895-P
- By:
- Publication type:
- Article
Mechanisms of Insulin Resistance After Insulin-Induced Hypoglycemia in Humans: The Role of Lipolysis.
- Published in:
- Diabetes, 2010, v. 59, n. 6, p. 1349, doi. 10.2337/db09-0745
- By:
- Publication type:
- Article